The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
November 23rd 2024
With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.
November 18th 2024
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
No Benefit from Niacin in Seniors with Coronary Artery Disease
November 25th 2009A study from Johns Hopkins has found that "routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease."
Translating Education into Clinical Practice: The Role of Learning Communities
November 24th 2009Collaboration is important in healthcare, as evidenced by the growing number of "learning communities" and grassroots efforts that are bringing people and organizations together to work on the issue of eliminating disparities in health and healthcare.
Vioxx Adverse Events May Have Been Identified Years Earlier
November 23rd 2009As of December 2000, 21 of 30 randomized, placebo-controlled trials had been completed and the risk of a cardiovascular thromboembolic adverse event or death was greater among subjects assigned to the rofecoxib group, raising concerns from a safety standpoint.
Drowning in the Sargasso Sea of Health Information: Help Is on the Way
November 20th 2009In his July 2009 editorial, Dr. Robert C. Like, MD, MS, wrote about the importance of creating "communities of practice" and the increasing role of the Web and collaboration in facilitating the development of learning networks. Here, he continues this discussion by sharing some perspectives from the field of library science about the impact of the Internet on clinical practice and public health.
Clinical Trial Disparities: A Case for Diversity
The challenge of eliminating disparities in clinical trials is being addressed by the Eliminating Disparities in Clinical Trials (EDICT) project, which recognizes that broadening diversity in clinical trials will result in improved effectiveness and safety of future medicines, improved trial quality, and reduced discrepancies in health equity.
Revised AHA/ACC PCI and STEMI Guidelines Released
November 18th 2009Wednesday at the American Heart Association Scientific Sessions 2009, the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines announced the release of the long-awaited update to the guidelines for management of patients with ST-elevation myocardial infarction and the management of patients undergoing percutaneous coronary intervention.
Atrial Fibrillation - Abstract Poster Session
November 18th 2009Nearly a dozen posters were presented during this final-day poster session, featuring results of studies looking at such topics as postmenopausal hormone therapy, pericardial fat, birth weight in women, chronic kidney disease, metabolic syndrome, pulmonary toxicity associated with amiodarone, and risk stratification schemes. The results of these studies are highlighted.
Catheter Ablation of Atrial Fibrillation: Emerging Technologies
This abstract poster session featured the topics of left atrial scar remodeling, closure of gap lesions, incidence of complete circumferential scar of the pulmonary vein antra, contact force mapping and ultrasound, antral isolation of pulmonary veins, radiofrequency ablation versus visutally guided laser balloon ablation, regional differences in left atrial wall thickness, and more. Highlights of these research posters are offered below.
What Can Ischemia and Ventricular Tachycardia Tell Us about Cardiovascular Risk?
November 17th 2009Study results from the MERLIN-TIMI 36 Trial looking at the risk of ischemia and nonsustained ventricular tachycardia (NSVT) alone or combined in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) were presented during an abstract oral session at the American Heart Association Scientific Sessions 2009.
Coronary Micro-vessel Spasm and Angina-like Chest Pain
November 17th 2009A study presented Tuesday at the American Heart Association Scientific Sessions 2009 looked at the relationship between coronary micro-vessel spasm, epicardial coronary artery spastic angina, and non-obstructive coronary artery disease.
Atrial Fibrillation: Bench to Bedside
This session focused on the current state of practice for atrial fibrillation (AF) ablation; the pathophysiology of AF, including genetics, atrial structure, and neurologic input; and clinical and epidemiological insights into imaging AF substrate.
Echocardiography in Clinical Syndromes: Atrial Fibrillation
This abstract oral session, featuring presenters who were given 15 minutes to review their research, provided attendees with information on the E/e’ ratio as a prognostic predictor in patients with atrial fibrillation (AF), the association between atrial and ventricular ECG findings and cardiac circulating biomarkers, stiffness of the left atrium, left atrial function as a predictor of first AF in older adults, and the mechanism of improvement of cardiac function in patients with AF. The studies are reviewed here.
Atrial Fibrillation: Mechanisms and Implications for Ablation
This abstract session featured presenters for studies that focused on the importance of atrial surface area and refractory period in sustaining atrial fibrillation (AF), mechanisms of CFAE formation in the posterior left atrium during induced AF, the left atrial ganlionated plexus, and complex fractionated atrial electrogramm versus liner ablation for persistent AF.
The results of a study that looked at the competing effects on left ventricular hypertrophy (LVH) of hypokalemia and treatment with hydrochlorothiazides (HCTZ) in hypertensive patients were presented Monday, November 15 at the American Heart Association Scientitifc Sessions 2009.
Treatment of Arrhythmias: Pharmacologic
This all-day abstract poster session featured researchers presenting results of studies focused on such topics as atrial fibrillation following pulmonary transplantation, use of Digoxin in atrial fibrillation, supplementation of Omega 3 PUFA plus antioxidante vitamins to prevent postoperative atrial fibrillation, and the impact of hypothyroidism on atrial fibrillation treatment strategy outcomes. The results are highlighted here.
Although treatment with low-dose aspirin is standard care for secondary prevention of cardiovascular (CV) events, some studies have shown that up to half of all patients stop taking aspirin. Other studies have shown that discontinuation of aspirin in these patients is linked to an increased risk of MI and other ischemic events.